Tolerability and safety of aripiprazole in schizophrenic patients Şizofreni hastalarinda aripiprazol'ün tolerabilitesi ve güvenirliǧi
Klinik Psikofarmakoloji Bulteni, cilt.18, sa.SUPPL. 1, 2008 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 18 Sayı: SUPPL. 1
- Basım Tarihi: 2008
- Dergi Adı: Klinik Psikofarmakoloji Bulteni
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Anahtar Kelimeler: Aripiprazole, Safety, Tolerability
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Use of atypical antipsychotics in treatment of schizophrenia has given clinicians new alternatives in treatment. Although atypical antipsychotics have strong D2 antagonism and effects on the other receptors, particularly serotonergic receptors, one would suppose less extrapyramidal side effects and a lesser degree of prolactin increase, two side effects that would interfere with compliance also have been noted. Aripiprazole has a different receptor profile and show both agonistic and antagonistic effects on D2 receptors. Aripiprazole have been found a tolerable and safe new agent ,with different dopaminergic mechanisms, different effects on other receptors, sedation, extrapyramidal side effects, metabolic abnormalities, weight gain and cardiac rythym abnormalities. Moreover aripiprazole may normalize some metabolic abnormalities and glucose dysregulation. As aripiprazole can be administered without titration and have a favorable side effect profile, it may increase compliance of the patients in both acute states and long term of treatment of schizophrenia.